Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day

Benzinga · 1d ago

Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence today announced that a poster presentation of interim data from its ongoing ReSPECT-LMM multidose study of REYOBIQ™ (rhenium Re186 obisbemeda) will be presented at the Society for Neuro-Oncology ("SNO") 31st Annual Meeting and Education Day, taking place November 12–15, 2026, at the Pennsylvania Convention Center in Philadelphia.